Supportive Care in Cancer

, Volume 17, Issue 4, pp 451–460 | Cite as

Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB)

  • Andrea L. Cheville
  • Jeff A. Sloan
  • Donald W. Northfelt
  • Anand P. Jillella
  • Gilbert Y. Wong
  • James D. Bearden III
  • Heshan Liu
  • Paul L. Schaefer
  • Benjamin T. Marchello
  • Bradley J. Christensen
  • Charles L. Loprinzi
Original Article



Current therapies often have limited efficacy and untenable side effects when used to treat persistent incisional pain following cancer-related surgery. Lidocaine patches reduce neuropathic pain from herpes zoster but their benefits for persistent cancer-related postsurgical incisional pain remain unclear.

Study design

Multicenter, double-blind, randomized, two-period crossover trial.

Materials and methods

Twenty-eight cancer patients with postsurgical incisional pain were randomly assigned to receive either lidocaine patches followed by placebo patches or the reverse. Each study period lasted 4 weeks. Patches were applied daily upon waking and left in place for a maximum of 18 h. The primary outcome measure, an 11-point pain intensity rating scale, was administered weekly. Secondary outcomes were administered weekly (Brief Pain Inventory-Short Form(BPI-SF), Subject Global Impression of Change) and at the end of each study period (Short Form-Magill Pain Questionnaire, Linear Analogue Self Assessment Scale, Neuropathy Pain Scale, Pain Catastrophizing Scale, Profile of Mood States Short Form).


Twenty-one patients completed the first period and 18 completed their crossover second phase. No significant intergroup differences were detected in pain intensity ratings. Few secondary end points were significantly different when subjects used the lidocaine versus placebo patches. BPI-SF interference scores were lower in patients using the lidocaine patch during the first study period, including several scores that achieved statistical significance, general activity (p = 0.02), work (p = 0.04), and relations with others (p = 0.02).


Lidocaine patch use did not significantly reduce pain intensity ratings or the majority of related secondary end points in cancer patients with persistent incisional pain.


Lidocaine patch Postsurgical neuropathic pain Cancer Cancer-related pain 


  1. 1.
    Argoff CE (2004) Conclusions: chronic pain studies of lidocaine patch 5% using the Neuropathic Pain Scale. Curr Med Res Opin 20(Suppl 2):S29–S31. doi: 10.1185/030079904X12979 PubMedCrossRefGoogle Scholar
  2. 2.
    Baker F, Denniston M, Zabora J, Polland A, Dudley WN (2002) A POMS short form for cancer patients: psychometric and structural evaluation. Psychooncology 11:273–281. doi: 10.1002/pon.564 PubMedCrossRefGoogle Scholar
  3. 3.
    Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF (1996) Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 276:637–639. doi: 10.1001/jama.276.8.637 PubMedCrossRefGoogle Scholar
  4. 4.
    Campbell JN, Raja SN, Meyer RA, Mackinnon SE (1988) Myelinated afferents signal the hyperalgesia associated with nerve injury. Pain 32:89–94. doi: 10.1016/0304-3959(88)90027-9 PubMedCrossRefGoogle Scholar
  5. 5.
    Cleeland C et al (1992) How to assess cancer pain. In: Turk DC, Melzack R (eds) Handbook of pain assessment. Guilford, New York, pp 360–387Google Scholar
  6. 6.
    Coderre TJ, Katz J, Vaccarino AL, Melzack R (1993) Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain 52:259–285. doi: 10.1016/0304-3959(93)90161-H PubMedCrossRefGoogle Scholar
  7. 7.
    Dajczman E, Gordon A, Kreisman H, Wolkove N (1991) Long-term postthoracotomy pain. Chest 99:270–274. doi: 10.1378/chest.99.2.270 PubMedCrossRefGoogle Scholar
  8. 8.
    Dworkin RH, Corbin AE, Young JP Jr, Sharma U, LaMoreaux L, Bockbrader H, Garofalo EA, Poole RM (2003) Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 60:1274–1283PubMedGoogle Scholar
  9. 9.
    Fairclough DPH, Cella D, Bonomi P (1998) Comparison of several model-based methods for analyzing incomplete quality of life data in cancer trials. Stat Med 17:781–796. doi: 10.1002/(SICI)1097-0258(19980315/15)17:5/7<781::AID-SIM821>3.0.CO;2-O PubMedCrossRefGoogle Scholar
  10. 10.
    Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM (2001) Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94:149–158. doi: 10.1016/S0304-3959(01)00349-9 PubMedCrossRefGoogle Scholar
  11. 11.
    Galer BS, Rowbotham MC, Perander J, Friedman E (1999) Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 80:533–538. doi: 10.1016/S0304-3959(98)00244-9 PubMedCrossRefGoogle Scholar
  12. 12.
    Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC (2002) The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clin J Pain 18:297–301. doi: 10.1097/00002508-200209000-00004 PubMedCrossRefGoogle Scholar
  13. 13.
    Gammaitoni AR, Alvarez NA, Galer BS (2003) Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol 43:111–117. doi: 10.1177/0091270002239817 PubMedCrossRefGoogle Scholar
  14. 14.
    Hurny C, Bernhard J, Coates A, Peterson HF, Castiglione-Gertsch M, Gelber RD, Rudenstam CM, Collins J, Lindtner J, Goldhirsch A, Senn HJ (1996) Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trial. Med Care 34:234–248. doi: 10.1097/00005650-199603000-00004 PubMedCrossRefGoogle Scholar
  15. 15.
    Jensen MP, Karoly P, Braver S (1986) The measurement of clinical pain intensity: a comparison of six methods. Pain 27:117–126. doi: 10.1016/0304-3959(86)90228-9 PubMedCrossRefGoogle Scholar
  16. 16.
    Jensen MP, Dworkin RH, Gammaitoni AR, Olaleye DO, Oleka N, Galer BS (2005) Assessment of pain quality in chronic neuropathic and nociceptive pain clinical trials with the Neuropathic Pain Scale. J Pain 6:98–106. doi: 10.1016/j.jpain.2004.11.002 PubMedCrossRefGoogle Scholar
  17. 17.
    Johansson A, Kornfalt J, Nordin L, Svensson L, Ingvar C, Lundberg J (2003) Wound infiltration with ropivacaine and fentanyl: effects on postoperative pain and PONV after breast surgery. J Clin Anesth 15:113–118. doi: 10.1016/S0952-8180(02)00511-1 PubMedCrossRefGoogle Scholar
  18. 18.
    Karmakar MK, Ho AM (2004) Postthoracotomy pain syndrome. Thorac Surg Clin 14:345–352. doi: 10.1016/S1547-4127(04)00022-2 PubMedCrossRefGoogle Scholar
  19. 19.
    Katz J, McCartney CJ (2002) Current status of pre-emptive analgesia. Curr Opin Anaesthesiol 15:435–441. doi: 10.1097/00001503-200208000-00005 PubMedCrossRefGoogle Scholar
  20. 20.
    Kehlet H, Jensen TS, Woolf CJ (2006) Persistent postsurgical pain: risk factors and prevention. Lancet 367:1618–1625. doi: 10.1016/S0140-6736(06)68700-X PubMedCrossRefGoogle Scholar
  21. 21.
    Loprinzi CL, Kugler JW, Sloan JA, Rooke TW, Quella SK, Novotny P, Mowat RB, Michalak JC, Stella PJ, Levitt R, Tschetter LK, Windschitl H (1999) Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. N Engl J Med 340:346–350. doi: 10.1056/NEJM199902043400503 PubMedCrossRefGoogle Scholar
  22. 22.
    Lussier D, Huskey AG, Portenoy RK (2004) Adjuvant analgesics in cancer pain management. Oncologist 9:571–591. doi: 10.1634/theoncologist.9-5-571 PubMedCrossRefGoogle Scholar
  23. 23.
    Macdonald L, Bruce J, Scott NW, Smith WC, Chambers WA (2005) Long-term follow-up of breast cancer survivors with post-mastectomy pain syndrome. Br J Cancer 92:225–230PubMedGoogle Scholar
  24. 24.
    Malenka RC (1991) The role of postsynaptic calcium in the induction of long-term potentiation. Mol Neurobiol 5:289–295. doi: 10.1007/BF02935552 PubMedCrossRefGoogle Scholar
  25. 25.
    Mandrekar JSD, Novotny PJ, Slaon JA (1999) A general Gibbs sampling algorithm for analyzing linear models using the SAS system. In: Proceedings of the SUGI, p 1644–1649Google Scholar
  26. 26.
    Mandrekar JSD, Novotny PJ, Slaon JA (1999) A general Gibbs sampling algorithm for analyzing linear models using the SAS system. SUGI Proc 24:1644–1649Google Scholar
  27. 27.
    Melzack R (1975) The McGill Pain Questionnaire: major properties and scoring methods. Pain 1:277–299. doi: 10.1016/0304-3959(75)90044-5 PubMedCrossRefGoogle Scholar
  28. 28.
    Melzack R (1987) The short-form McGill pain questionnaire. Pain 30:191–197. doi: 10.1016/0304-3959(87)91074-8 PubMedCrossRefGoogle Scholar
  29. 29.
    Nguyen A, Girard F, Boudreault D, Fugere F, Ruel M, Moumdjian R, Bouthilier A, Caron JL, Bojanowski MW, Girard DC (2001) Scalp nerve blocks decrease the severity of pain after craniotomy. Anesth Analg 93:1272–1276. doi: 10.1097/00000539-200111000-00048 PubMedCrossRefGoogle Scholar
  30. 30.
    Osman A, Barrios FX, Kopper BA, Hauptmann W, Jones J, O’Neill E (1997) Factor structure, reliability, and validity of the Pain Catastrophizing Scale. J Behav Med 20:589–605. doi: 10.1023/A:1025570508954 PubMedCrossRefGoogle Scholar
  31. 31.
    Pergolizzi J, Boger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P (2008) Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 8:287–313. doi: 10.1111/j.1533-2500.2008.00204.x PubMedCrossRefGoogle Scholar
  32. 32.
    Pocock SJ, Simon R (1975) Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103–115. doi: 10.2307/2529712 PubMedCrossRefGoogle Scholar
  33. 33.
    Reuben SS (2007) Chronic pain after surgery: what can we do to prevent it. Curr Pain Headache Rep 11:5–13. doi: 10.1007/s11916-007-0015-9 PubMedCrossRefGoogle Scholar
  34. 34.
    Rowbotham MC, Davies PS, Verkempinck C, Galer BS (1996) Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 65:39–44. doi: 10.1016/0304-3959(95)00146-8 PubMedCrossRefGoogle Scholar
  35. 35.
    Senn S (1993) Cross-over trials in clinical research. Wiley, New YorkGoogle Scholar
  36. 36.
    Sloan JA, Dueck A (2004) Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J Biopharm Stat 14:73–96. doi: 10.1081/BIP-120028507 PubMedCrossRefGoogle Scholar
  37. 37.
    Sloan JANP, Lorinzi CL, Nair S (1997) Graphical and analytical tools for the analysis two-period crossover clinical trials. SUGI Proc 22:1312–1317Google Scholar
  38. 38.
    Sloan JA OFJ, Suman VJ, Sargeant DJ (1998) Incorporating quality of life measurement in oncology clinical trials. In: Proceedings of the American Statistical Association, p 281–287Google Scholar
  39. 39.
    Wallace MS, Wallace AM, Lee J, Dobke MK (1996) Pain after breast surgery: a survey of 282 women. Pain 66:195–205. doi: 10.1016/0304-3959(96)03064-3 PubMedCrossRefGoogle Scholar
  40. 40.
    Wiffen PJ, McQuay HJ, Edwards JE, Moore RA (2005) Gabapentin for acute and chronic pain. Cochrane Database Syst Rev CD005452Google Scholar
  41. 41.
    Wiffen PJ, McQuay HJ, Moore RA (2005) Carbamazepine for acute and chronic pain. Cochrane Database Syst Rev CD005451Google Scholar
  42. 42.
    Woolf CJ, Salter MW (2000) Neuronal plasticity: increasing the gain in pain. Science 288:1765–1769. doi: 10.1126/science.288.5472.1765 PubMedCrossRefGoogle Scholar
  43. 43.
    Yaksh TL (2006) Calcium channels as therapeutic targets in neuropathic pain. J Pain 7:S13–S30. doi: 10.1016/j.jpain.2005.09.007 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Andrea L. Cheville
    • 1
  • Jeff A. Sloan
    • 1
  • Donald W. Northfelt
    • 2
  • Anand P. Jillella
    • 3
  • Gilbert Y. Wong
    • 1
  • James D. Bearden III
    • 4
  • Heshan Liu
    • 1
  • Paul L. Schaefer
    • 5
  • Benjamin T. Marchello
    • 6
  • Bradley J. Christensen
    • 1
  • Charles L. Loprinzi
    • 1
    • 7
  1. 1.Mayo Clinic and Mayo FoundationRochesterUSA
  2. 2.Mayo Clinic ScottsdaleScottsdaleUSA
  3. 3.Medical College of GeorgiaAugustaUSA
  4. 4.Upstate Carolina CCOPSpartanburgUSA
  5. 5.Toledo Community Hospital Oncology Program CCOPToledoUSA
  6. 6.Montana Cancer ConsortiumBillingsUSA
  7. 7.Mayo ClinicSW RochesterUSA

Personalised recommendations